⌘K

Login Start Free

Home/Filings/4/0001181431-10-051418

4//SEC Filing

CHEN DAVID 4

Accession 0001181431-10-051418

CIK 0001409012other

View on SEC.gov Company Profile

Filed

Oct 18, 8:00 PM ET

Accepted

Oct 19, 5:40 PM ET

Size

20.5 KB

Accession

0001181431-10-051418

Insider Transaction Report

Form 4

Period: 2010-10-15

Abraxis BioScience, Inc.ABII

Director

Transactions

Disposition to Issuer
Non-qualified Stock Option
2010-10-15−1,272→ 0 total
Exercise: $95.26From: 2007-11-29Exp: 2015-06-17→ Common Stock (1,272 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$25.84/sh−4,243$109,639→ 0 total
Exercise: $47.30From: 2007-11-29Exp: 2016-08-01→ Common Stock (4,243 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$35.06/sh−10,000$350,600→ 0 total
Exercise: $38.08From: 2010-12-10Exp: 2019-12-10→ Common Stock (10,000 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15−1,272→ 0 total
Exercise: $82.94From: 2007-11-29Exp: 2014-12-13→ Common Stock (1,272 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$43.70/sh−1,909$83,423→ 0 total
Exercise: $29.44From: 2007-11-29Exp: 2012-10-25→ Common Stock (1,909 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15−2,970→ 0 total
Exercise: $94.84From: 2007-11-29Exp: 2015-07-21→ Common Stock (2,970 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$38.49/sh−1,909$73,477→ 0 total
Exercise: $34.65From: 2007-11-29Exp: 2013-04-24→ Common Stock (1,909 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$17.70/sh−10,000$177,000→ 0 total
Exercise: $55.44From: 2007-11-29Exp: 2017-11-29→ Common Stock (10,000 underlying)

Footnotes (1)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010, among Celgene Corporation ("Celgene"), Artistry Acquisition Corp. ("Merger Sub") and Abraxis BioScience, Inc. ("Abraxis"), whereby Merger Sub merged into Abraxis, with Abraxis continuing as the surviving company and a wholly owned subsidiary of Celgene (the "Merger"), this option, which was granted, and became exercisable, on December 10, 2009, was cancelled in exchange for (i) a cash payment of $350,600.00, which represents the excess of $73.14 per share over the exercise price per share of this option and (ii) a contingent value right issued by Celgene.

Documents

1 file

4
rrd288877.xmlPrimary
FORM4

Issuer

Abraxis BioScience, Inc.

CIK 0001409012

Entity typeother

Related Parties

1

filerCIK 0001189015

Filing Metadata

Form type: 4
Filed: Oct 18, 8:00 PM ET
Accepted: Oct 19, 5:40 PM ET
Size: 20.5 KB

View on SEC.gov